Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
R Donald HarveyPhase 1 Clinical Trials Section, Winship Cancer Institute of Emory University, Atlanta, GA, USAAbstract: Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2&nd...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Kniha |
| Vydáno: |
Dove Medical Press,
2014-05-01T00:00:00Z.
|
| Témata: | |
| On-line přístup: | Connect to this object online. |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Jednotka 1 | Dostupné |